Senate Files

Bills

S. 43 119th Congress

Skinny Labels, Big Savings Act

Latest action, Jan 9, 2025: Read twice and referred to the Committee on the Judiciary.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

3 cosponsors

Sponsored by John W. Hickenlooper (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
1 D · 2 R
  • Democrat
  • Republican
  • Independent
3 senators cosponsoring

Referred to: Senate: Judiciary Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

21 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ASSOCIATION FOR ACCESSIBLE MEDICINES
7 reports
GSK (FKA GLAXOSMITHKLINE INC.)
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
7 reports
TEVA PHARMACEUTICALS USA, INC.
FAEGRE DRINKER BIDDLE & REATH LLP
7 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
7 reports
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
6 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
6 reports
NOVARTIS
6 reports
SANOFI US SERVICES INC
6 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
5 reports
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)
FIERCE GOVERNMENT RELATIONS
5 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
5 reports
APOTEX CORP.
4 reports
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
COVINGTON & BURLING LLP
4 reports
AMGEN INC
3 reports
All 25 of 27 clients
ClientLobbying firmReportsReports totalingFromToSenate
ASSOCIATION FOR ACCESSIBLE MEDICINES7$5.6MQ1 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)7$8.9MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA7$64.5MQ1 2025Q3 2026yes
TEVA PHARMACEUTICALS USA, INC.FAEGRE DRINKER BIDDLE & REATH LLP7$0Q1 2025Q3 2026yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.7$630KQ1 2025Q3 2026yes
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)6$60KQ4 2025Q3 2026yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC6$300KQ1 2025Q2 2026yes
NOVARTIS6$9.8MQ4 2025Q3 2026yes
SANOFI US SERVICES INC6$8.5MQ4 2025Q3 2026yes
ASSOCIATION OF ACCESSIBLE MEDICINESMEHLMAN CONSULTING, INC.5$300KQ4 2025Q3 2026yes
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)FIERCE GOVERNMENT RELATIONS5$300KQ1 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION5$9.4MQ4 2025Q3 2026yes
APOTEX CORP.4$2.0MQ4 2025Q2 2026yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP4$0Q1 2025Q3 2026yes
AMGEN INC3$8.2MQ1 2026Q3 2026yes
INTELLECTUAL PROPERTY OWNERS ASSOCIATION3$150KQ2 2025Q2 2026yes
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)2$710KQ2 2026Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)2$180KQ2 2026Q3 2026yes
FRESENIUS KABI USA LLC2$970KQ3 2025Q3 2026yes
KAISER FOUNDATION HEALTH PLAN INC2$1.0MQ2 2026Q3 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY GENERIC PHARMACEUTICAL ASSOC.)CAPITOL HILL CONSULTING GROUP1$60KQ4 2025Q4 2025yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION1$990KQ2 2026Q2 2026yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC1$80KQ2 2026Q2 2026yes
FRESENIUS KABI USA LLCWILEY REIN LLP1$0Q3 2026Q3 2026yes
GUIDEWELL MUTUAL HOLDING CORPORATION1$20KQ2 2026Q2 2026yes